In recognition of September as Blood Cancer Awareness Month, Andrew Jallouk, MD, assistant professor of medicine at Vanderbilt University, discusses the surge of approved therapies in lymphoma over ...

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Researchers explore innovative macrocyclic peptides to target small cell lung cancer, revealing promising therapeutic ...

Andrew Jallouk, MD, highlights the challenges in lymphoma treatment, including access disparities and the need for personalized therapies for better patient outcomes.

During a live event, Tian Zhang, MD, MHS, discussed darolutamide in mHSPC, with efficacy and cost being key considerations ...

During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of ...

The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in ...

FDA designates raludotatug deruxtecan as a breakthrough therapy for treating platinum-resistant ovarian cancers, enhancing ...

New 5-year data reveals cemiplimab plus chemotherapy significantly enhances survival rates for advanced non-small cell lung cancer patients.

A phase 2 study reveals autologous TIL therapy's potential to stabilize recurrent head and neck cancer, offering hope for improved treatment options.

Combination therapy of casdatifan and cabozantinib shows promising efficacy and manageable safety in patients with advanced ...